These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 36016624)

  • 1. Anti-PD-1 sintilimab-induced bilateral optic neuropathy in non-small cell lung cancer: A case report and literature review.
    Wang J; Xiao X; Dong X; Wu G; Wang X; Zhang R
    Front Oncol; 2022; 12():931074. PubMed ID: 36016624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Indirect comparison of sintilimab and other PD-L1 inhibitors for first-line treatment of non-squamous non-small-cell lung cancer.
    Zhang L; Qian Y; Li J; Cui C; Chen L; Qu S; Lu S
    Future Oncol; 2022 May; 18(15):1896-1905. PubMed ID: 35311347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Case report: A rare case of anti-PD-1 sintilimab-induced agranulocytosis/severe neutropenia in non-small cell lung cancer and literature review.
    Qin Y; Lu S; Chen J; Peng J; Yang J
    Front Oncol; 2024; 14():1415748. PubMed ID: 38957321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sintilimab for the treatment of non-small cell lung cancer.
    Zhang L; Lin W; Tan F; Li N; Xue Q; Gao S; Gao Y; He J
    Biomark Res; 2022 Apr; 10(1):23. PubMed ID: 35436956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Corneal ulcer development due to sintilimab-anlotinib combination therapy-induced dry eye: a case report.
    Xiang X; Lin W; Guan X; Zhou B; Yuan Y; Silva D; Wang Y
    Transl Cancer Res; 2024 May; 13(5):2571-2579. PubMed ID: 38881937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-term outcomes of neoadjuvant sintilimab with chemotherapy in stage III non-small cell lung cancer: a case series.
    Fan BS; Wang XT; Di SY; Zhao JH; Chen SY; Zhou SH; Yue CY; Song WA; Gong TQ
    Transl Cancer Res; 2022 Jun; 11(6):1697-1704. PubMed ID: 35836545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Case report: A rare case of sintilimab-induced gastric stenosis and literature review.
    Song K; Dong H; Jiang S; Xu X; Zhang C; Chen Q; Wang Q
    Front Oncol; 2023; 13():1091459. PubMed ID: 36761970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Final overall survival data of sintilimab plus pemetrexed and platinum as First-Line treatment for locally advanced or metastatic nonsquamous NSCLC in the Phase 3 ORIENT-11 study.
    Zhang L; Wang Z; Fang J; Yu Q; Han B; Cang S; Chen G; Mei X; Yang Z; Stefaniak V; Lin Y; Wang S; Zhang W; Sun L; Yang Y
    Lung Cancer; 2022 Sep; 171():56-60. PubMed ID: 35917647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toxic epidermal necrolysis induced by sintilimab in a patient with advanced non-small cell lung cancer and comorbid pulmonary tuberculosis: A case report.
    Li G; Gong S; Wang N; Yao X
    Front Immunol; 2022; 13():989966. PubMed ID: 36090976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pituitary immune-related adverse events induced by programmed cell death protein 1 inhibitors in advanced lung cancer patients: A report of 3 cases].
    Gu YC; Liu Y; Xie C; Cao BS
    Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 54(2):369-375. PubMed ID: 35435206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sintilimab-Induced Autoimmune Diabetes in a Patient With the Anti-tumor Effect of Partial Regression.
    Wen L; Zou X; Chen Y; Bai X; Liang T
    Front Immunol; 2020; 11():2076. PubMed ID: 32973816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC.
    Gao S; Li N; Gao S; Xue Q; Ying J; Wang S; Tao X; Zhao J; Mao Y; Wang B; Shao K; Lei W; Wang D; Lv F; Zhao L; Zhang F; Zhao Z; Su K; Tan F; Gao Y; Sun N; Wu D; Yu Y; Ling Y; Wang Z; Duan C; Tang W; Zhang L; He S; Wu N; Wang J; He J
    J Thorac Oncol; 2020 May; 15(5):816-826. PubMed ID: 32036071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unexpected favorable outcome to sintilimab plus bevacizumab in an EGFR-mutated non-small cell lung cancer patient: A case report.
    Zhang Y; Zhao M; Cao S; Zhang X; Du Y
    Thorac Cancer; 2020 Sep; 11(9):2717-2722. PubMed ID: 32656988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A case of acute myocarditis induced by PD-1 inhibitor (sintilimab) in the treatment of large cell neuroendocrine carcinoma.
    Zheng S; Zhang H; Hu B; Zhou J; Wen L; Li M
    Heliyon; 2023 Jun; 9(6):e16874. PubMed ID: 37342584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toxic Epidermal Necrolysis and Stevens - Johnson Syndrome Following Sintilimab Administration in a Non-Small Cell Lung Cancer Patient: A Case Report.
    Jiang Z; Chen X; Sun Z; Shen X; Huang Y; Liu J
    J Inflamm Res; 2023; 16():5061-5067. PubMed ID: 37936597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sintilimab induced diabetic ketoacidosis in a patient with small cell lung cancer: A case report and literature review.
    Huang X; Yang M; Wang L; Li L; Zhong X
    Medicine (Baltimore); 2021 May; 100(19):e25795. PubMed ID: 34106616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toxic epidermal necrolysis associated with chemoimmunotherapy for lymphoma: case report and literature review.
    Yang W; Xu X; Xia D; Wang H; Jiang J; Yang G
    Immunotherapy; 2022 Apr; 14(5):275-282. PubMed ID: 35128931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sintilimab-induced autoimmune diabetes: A case report and review of the literature.
    Yang J; Wang Y; Tong XM
    World J Clin Cases; 2022 Feb; 10(4):1263-1277. PubMed ID: 35211559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 1b Study of Sintilimab Plus Anlotinib as First-line Therapy in Patients With Advanced NSCLC.
    Chu T; Zhong R; Zhong H; Zhang B; Zhang W; Shi C; Qian J; Zhang Y; Chang Q; Zhang X; Dong Y; Teng J; Gao Z; Qiang H; Nie W; Zhao Y; Han Y; Chen Y; Han B
    J Thorac Oncol; 2021 Apr; 16(4):643-652. PubMed ID: 33524601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sintilimab: A Promising Anti-Tumor PD-1 Antibody.
    Zhang L; Mai W; Jiang W; Geng Q
    Front Oncol; 2020; 10():594558. PubMed ID: 33324564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.